ABBV-295
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
AbbVie · Phase 1 · Active, not recruiting · Enrollment 24
No selected arm has a reported week for this endpoint.
A solid line connects the weeks the source reports.